Paul A. Meyers

TL;DR: The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcomeFor patients with nonmetastatic Ewing's Sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.

TL;DR: The current state of the art of systemic osteosarcoma therapy is reviewed by focusing on the experiences of cooperative osteosARcoma groups, shedding light on questions and challenges posed by the aggressiveness of the tumor, and potential future directions that may be critical to progress in the prognosis of high-grade osteosArcoma.

TL;DR: Intensive chemotherapy can achieve DFS for a high proportion of patients with osteogenic sarcoma and histologic response to preoperative chemotherapy cannot be assessed at diagnosis, although it is a powerful predictor of DFS.

TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.

TL;DR: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma, and the addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.